Hospital

Donanemab-azbt shows sustained benefits in slowing cognitive decline in Alzheimer disease, emphasizing the value of early intervention and treatment.

New research highlights a surge in pediatric pneumococcal pneumonia cases post COVID-19, urging a shift toward supportive treatment strategies.

Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission.

Eileen Peng, PharmD, discusses how her team has restructured pharmacy services to support outpatient administration of CAR T-cell and bispecific therapies—emphasizing multidisciplinary collaboration, early toxicity management, real-world data integration, and pharmacist-led care transitions to ensure safety and continuity across care settings.

Two pharmacy leaders at UNC Health share how their distinct yet complementary leadership journeys and skill sets are driving innovation in clinical practice, education, and team development across the health system.

Maximizing pharmacists’ impact on medication safety requires removing barriers to intervention and empowering proactive clinical roles.

FDA approves inclisiran as a monotherapy to effectively lower low-density lipoprotein cholesterol in adults with hypercholesterolemia, enhancing heart disease prevention strategies.

The authors note that the findings can have significant public health implications given the widespread water chlorination and increased chronic kidney disease burden.

Sanofi's SAR446523 receives orphan drug designation for relapsed/refractory multiple myeloma, enhancing treatment options and patient outcomes.

RSV hospitalization in older adults links to increased cardiovascular events, highlighting the need for vigilant monitoring and vaccination strategies.

Pirtobrutinib shows promising results in a head-to-head trial against ibrutinib for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).

Decentralized pharmacists play a critical role in reducing medication errors by collaborating in real time with physicians and nurses to enhance patient safety across care settings.

Luspatercept shows promise in reducing transfusion dependence for myelofibrosis-associated anemia, despite not meeting primary trial end points.

Kevin Chen, PharmD, MS, BCOP, CPP; and Amanda Cass, PharmD, BCPS, BCOP, share key insights about ROS1, non-small cell lung cancer, and the newly approved drug taletrectinib.

Astegolimab shows promise in reducing chronic obstructive pulmonary disease (COPD) exacerbations, offering hope for improved management of this debilitating lung disease.

Hospitalized older adults infected with SARS-CoV-2 had faster declines in executive function and memory compared with both uninfected and nonhospitalized infected patients.

Pharmacists share their institution's individual, unique approaches to medication safety.

Emerging trial results reveal gedatolisib significantly enhances progression-free survival (PFS) in advanced HR+/HER2- breast cancer.

Pharmacist share actionable insights for EMR utilization and facilitation of medication safety practices.

Experts discuss groundbreaking Hot Line trials at the European Society of Cardiology Congress 2025, offering insights into the latest cardiovascular research.

FDA places clinical hold on Sarepta's Elevidys gene therapy after safety concerns, but ambulatory patients regain access amid ongoing investigations.

A phase 2 trial shows oxylanthanum carbonate (OLC) effectively manages hyperphosphatemia in patients with chronic kidney disease (CKD), offering a promising treatment option.

A meta-analysis suggests that long-term P2Y12 inhibitor monotherapy after percutaneous coronary intervention may offer superior protection against major adverse cardiac and cerebrovascular events compared with aspirin, without increasing major bleeding risk—potentially challenging current guideline recommendations for antiplatelet therapy beyond 1 year.

Experts discuss HIV management challenges, including HBV coinfections, anal cancer risks, and weight gain, highlighting innovative treatment strategies.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the expanding role of GLP-1 receptor agonists in holistic type 2 diabetes care, highlighting their cardio-renal-hepatic benefits, clinical access challenges, emerging investigational therapies, and practical strategies for individualized, guideline-based prescribing.

FDA approves lonapegsomatropin for once-weekly treatment of growth hormone deficiency, offering a promising alternative for improved patient adherence and outcomes.